AKT1 and hepatocellular carcinoma: Recently, dasatinib was shown to be successful in reducing HCC cell proliferation, adhesion, migration and invasion in vitro via inhibiting Src and several downstream signaling pathways, including PI3K/PTEN/Akt and SFK/FAK [40].